Answers are grounded in this paper and cite their sources.
In conclusion, we identified the first lymphatic vascular defect in type 2 diabetes, an enhanced permeability caused by low NO bioavailability. Further, this demonstrates that PDE3 inhibition is required to maintain lymphatic vessel integrity and represents a viable therapeutic target for lymphatic endothelial dysfunction in metabolic disease.
No takes yet. Share an insight, caveat, or question.
Scallan et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: